A Cleveland Clinic study reveals a mechanism that rapidly destroys high-density lipoprotein (HDL) in people with Type 2 diabetes, negating cardiovascular protections.
The ACCELERATE trial found no effect on cardiac events with evacetrapib despite large HDL gains and solid LDL declines. A substudy presented at ESC 2017 now shows the drug fared no better when analysis was limited to diabetic patients.
Long-standing hope for MDCO-216, which contains the ApoA-1 Milano variant of HDL, disappears as the compound fails to yield coronary plaque regression. But the jury’s still out on other HDL-targeted therapies.